Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Houerhuan Anti-inflammatory Capsules (猴耳环消炎胶囊) is a traditional Chinese medicine (TCM) product developed and manufactured by Beijing Laitai Pharmaceutical Technology. The drug is formulated from the extract of *Archidendron lucidum* (Benth.) Nielsen, a plant native to southern China known for its heat-clearing, detoxifying, and anti-inflammatory properties. Clinically, it is indicated for the treatment of acute pharyngitis, acute tonsillitis, upper respiratory tract infections, and acute gastroenteritis caused by heat-toxicity. The pharmacological action is attributed to the presence of active constituents such as tannins, polyphenols, and flavonoids, which exhibit broad-spectrum antibacterial activity against pathogens including *Staphylococcus aureus* and *Escherichia coli*, while also providing analgesic and anti-inflammatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on houerhuan anti-inflammatory capsules.